- Home
- ALT vs NATH Comparison
ALT vs NATH Comparison
Compare ALT & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | NATH |
|---|---|---|
| Founded | 1997 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 411.8M |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ALT | NATH |
|---|---|---|
| Price | $3.61 | $100.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 38.2K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | ★ 25.37 | 22.29 |
| EPS | N/A | ★ 4.17 |
| Revenue | $41,000.00 | ★ $104,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $756,308.50 | N/A |
| P/E Ratio | ★ N/A | $24.07 |
| Revenue Growth | ★ 105.00 | 7.81 |
| 52 Week Low | $2.91 | $88.00 |
| 52 Week High | $7.73 | $118.32 |
Technical Indicators
Market Signals| Indicator | ALT | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 34.82 | 52.21 |
| Support Level | $3.39 | $100.25 |
| Resistance Level | $4.25 | $101.86 |
| Average True Range (ATR) | 0.24 | 0.43 |
| MACD | -0.06 | -0.19 |
| Stochastic Oscillator | 13.75 | 16.45 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.